Figure 1From: The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence Kaplan-Meier survival curves for HER2 positive breast cancer cases stratified by staining with antibody directed at TRMT2A. TRMT2A expression is associated with outcome in a) the CCIH training cohort, b), the CCF confirmation cohort, and c) the RPCI validation cohort.Back to article page